

13386 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

TABLE 4.—COMPARISON BETWEEN PLACEBO AND EACH OF THE DRUG GROUPS FOR EACH TEST AND BETWEEN TEST 1 AND SUBSEQUENT TESTS IN EACH GROUP

Group	Number of subjects with normal fasting triglycerides level indicated			
	Test 1 vs. test 2	Test 1 vs. test 3	Test 1 vs. test 4	Test 1 vs. test 5
Placebo.....	21 vs. 22 33	19 vs. 17 26	15 vs. 15 19	12 vs. 12 17
Chlorpropamide.....	9 vs. 9 16	9 vs. 11 15	8 vs. 7 12	7 vs. 6 10
Tolbutamide.....	21 vs. 23 25	19 vs. 20+ 22	20++ vs. 20++ 20	17++ vs. 16++ 17
Phenformin.....	16 vs. 18 22	15 vs. 18+ 20	13 vs. 14 18	12 vs. 12 16
Acetohexamide.....	9 vs. 11++ 11	10 vs. 10+ 11	7 vs. 7 8	5 vs. 5 7

Degree of significance between placebo and drug groups (between group comparison) is indicated as: +=p<0.05, ++=0.01.

TABLE 5.—COMPARISON BETWEEN PLACEBO AND EACH OF THE DRUG GROUPS FOR EACH TEST AND BETWEEN TEST 1 AND SUBSEQUENT TESTS IN EACH GROUP

Group	Number of subjects with normal fasting cholesterol level indicated			
	Test 1 vs. test 2	Test 1 vs. test 3	Test 1 vs. test 4	Test 1 vs. test 5
Placebo.....	22 vs. 22 33	18 vs. 19 26	12 vs. 13 19	10 vs. 12 17
Chlorpropamide.....	12 vs. 15+ 16	11 vs. 12 15	9 vs. 10 12	7 vs. 9 10
Tolbutamide.....	21 vs. 21 25	18 vs. 19 22	16 vs. 16 20	14 vs. 14 17
Phenformin.....	19 vs. 19 22	17 vs. 16 20	15 vs. 18 18	13 vs. 11 16
Acetohexamide.....	11++ vs. 11++ 11	11+ vs. 11+ 11	8+ vs. 8+ 8	7+ vs. 7+ 7

Degree of significance between placebo and drug groups (between group comparison) is indicated as: +=p<0.05, ++=p<0.01.